Abstracts tagged "lymphocytes"

Abstract Number: 154 • 2020 Pediatric Rheumatology Symposium
T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis
Anna Patrick¹, Tashawna Esmond ², David Flaherty ², Thomas Brent Graham ², Susan Thompson ³ and Thomas Aune ¹, ¹Vanderbilt University Medical Center, Nashville, Tennessee, ²Vanderbilt University Medical Center, Nashville, ³Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common autoimmune arthritis in children. Polyarticular JIA and extended oligoarticular JIA both have genetic associations near genes…
Abstract Number: 610 • 2019 ACR/ARP Annual Meeting
Ankylosing Spondylitis-associated Killer Immunoglobin-like Receptors Are Strongly Expressed on γδ T Cells
Micah Lefton¹, Nihaarika Sharma ¹ and Joerg Ermann ², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston
Background/Purpose: The mechanism underlying the association between ankylosing spondylitis (AS) and HLA-B27 is still unknown. One of the hypotheses involves the interaction of HLA-B27 homodimers…
Abstract Number: 2519 • 2019 ACR/ARP Annual Meeting
Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE
Daniel Strasser ¹, Virginie Sippel ¹, Ursula Grieder ¹, Andrea Kieninger-Graefitsch ², Gabin Pierlot ¹, Hervé Farine ¹, Paulina Kulig ¹, Geoffroy Bourquin ¹, Marcel Keller ¹, Peter Groenen ¹, Marten Trendelenburg ² and Mark Murphy¹, ¹Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland, ²University Hospital Basel, Basel, Switzerland
Background/Purpose: SLE is an autoimmune disease driven by autoreactive T and B lymphocytes. Lymphocytes infiltrate self-antigen expressing tissues, in which tertiary lymphoid structures are often…
Abstract Number: 2570 • 2019 ACR/ARP Annual Meeting
Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis
Amira El Gerby ¹, Abeer Abdelati ², Hanaa Donia ³ and Nouran Eshak⁴, ¹Rheumatology Department, Faculty of Medicine, Alexandria University, Egypt, Alexandria, Egypt, ²alexandria university, alexandria, Egypt, ³Clnical and Chemical Pathology Department, Faculty of Medicine, ALexandria University, Alexandria, Egypt, ⁴Rheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Lubbock, TX
Background/Purpose: Proliferative lupus nephritis (LN) is one of the most common and serious manifestations of SLE and is a major cause of morbidity. A search…
Abstract Number: 685 • 2018 ACR/ARHP Annual Meeting
Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
William FC Rigby¹, Gerd R. Burmester², Oliver FitzGerald³, Valderilio F Azevedo⁴, Peter Nash⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Cunshan Wang⁷ and Thomas Jones⁶, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Charité – University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, St Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College, Dublin, Ireland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵University of Queensland, Brisbane, Australia, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is…
Abstract Number: 1110 • 2018 ACR/ARHP Annual Meeting
Characterization of CD20+ T Cells in Patients with Systemic Sclerosis
Monica D'Orazio¹, Elisabeth Fliesser², Florentine Moazedi-Fürst³, Martin Stradner⁴, Sonja Kielhauser³, Johannes Fessler⁵ and Hans-Peter Brezinschek¹, ¹Internal Medicine/Division of Rheumatoloy and Immunology, Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, ²Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, ⁴Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁵Department of Neurology, Harvard Medical School, Boston, MA
Background/Purpose: Recently, it has been demonstrated that a subset of T cells expresses the B-cell marker CD20. It has been postulated that in rheumatoid arthritis…
Abstract Number: 2038 • 2018 ACR/ARHP Annual Meeting
Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis
Satoshi Kubo¹, Shingo Nakayamada¹, Yusuke Miyazaki¹, Maiko Yoshikawa², Hiroko Yoshinari³, Shigeru Iwata⁴, Kentaro Hanami², Shunsuke Fukuyo³, Ippei Miyagawa⁵, Kazuhisa Nakano¹ and Yoshiya Tanaka⁶, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Fukuoka, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), molecular targeted therapies induced different changes in different immune cell phenotypes. For instance, our previous study showed…
Abstract Number: 2586 • 2018 ACR/ARHP Annual Meeting
Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis
Gerd R. Burmester¹, William FC Rigby², Ernest Choy³, Peter Nash⁴, Kevin Winthrop⁵, Philip J. Mease⁶, Pamela Young⁷, Thijs Hendrikx⁷, Cunshan Wang⁸, Sujatha Menon⁸ and Daniela Graham⁸, ¹Charité – University Medicine Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴University of Queensland, Brisbane, Australia, ⁵Oregon Health and Science University, Portland, OR, ⁶Swedish Medical Center and University of Washington, Seattle, WA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of psoriatic arthritis (PsA). Cytokines involved in lymphocyte development, function, and homeostasis signal…
Abstract Number: 1427 • 2017 ACR/ARHP Annual Meeting
Monitoring of Absolute Lymphocyte Count in Patients with Rheumatoid Arthritis Treated with Tofacitinib
Gerd R. Burmester¹, Zoltan Szekanecz², Pinaki Biswas³, Sriram Krishnaswami⁴, Christopher F Mojcik³, Hernan Valdez³, Jamie Geier³ and Sander Strengholt⁵, ¹Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²University of Debrecen Faculty of Medicine, Debrecen, Hungary, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Capelle aan den IJssel, Netherlands
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Lymphopenia is a frequent feature of RA,1 and RA medications may also…
Abstract Number: 2125 • 2017 ACR/ARHP Annual Meeting
Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study
Okinori Murata¹, Atsuko Kudo² and Katsuya Suzuki³, ¹Department of Pulmonary medicine, Hachinohe Red Cross Hospital, Hachinohe, Japan, ²Hachinohe Red Cross Hospital, Hachinohe, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medcine, Tokyo, Japan
Background/Purpose: Sarcoidosis is a systemic granulomatous disease that can affect multiple organs, and in particular lung involvements are common and found in more than 90%…
Abstract Number: 2596 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Hua Chen¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has been used for decades to treat various rheumatic diseases including systemic lupus erythematosus (SLE). The efficacy of HCQ…
Abstract Number: 660 • 2017 ACR/ARHP Annual Meeting
Strain-Dependent IL-17A Secretion By CD4-CD8- DN αβ T Cells Correlates with Disease Susceptibility in Murine Spondyloarthritis
Imtiyaz Hossain, Mederbek Matmusaev and Joerg Ermann, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hydrodynamic injection of IL-23 minicircles into adult B10.RIII mice induces an inflammatory disease with phenotypic features of human spondyloarthritis. Tissue-resident CD4-CD8- double negative (DN)…
Abstract Number: 961 • 2017 ACR/ARHP Annual Meeting
Adalimumab Reduces CXCR4 Expression during Inflammatory Arthritis and in Fibroblast-like Synoviocytes and Osteoclasts Under Chronic TNF Exposure
Bohdan P. Harvey¹, Li Li¹, Mark Konrad¹, Heather Knight¹, Susan Westmoreland², Melanie Ruzek¹ and Zehra Kaymakcalan¹, ¹AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: The CXCL12/CXCR4 chemokine axis has been implicated in the pathogenesis of RA. The expression of this chemokine and receptor has been shown to be…
Abstract Number: 286 • 2016 ACR/ARHP Annual Meeting
Clinical Significance and Prognostic Value of Neutrophil to Lymphocyte Ratio in Patients with Dermatomyositis
Jaehyung Hur¹, Dong Jin Go², Sang Wan Chung³, You Jung Ha³, Eun Ha Kang¹, Jin Kyun Park⁴, Eun Young Lee², Eun Bong Lee², Yeong Wook Song⁴ and Yun Jong Lee⁵, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: Recent studies have suggested that neutrophil to lymphocyte ratio (NLR) could be an emerging predictive marker of disease activity or mortality in patients with…
Abstract Number: 1036 • 2016 ACR/ARHP Annual Meeting
Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis
Paul-Peter Tak^1,2,3, Marieke E. Doorenspleet⁴, Maria de Hair⁵, Paul L. Klarenbeek⁶, Marian van Beers-Tas⁷, Antoine H.C. van Kampen⁸, Dirkjan van Schaardenburg^9,10, Danielle M. Gerlag^11,12, Frank Baas¹³ and Niek de Vries¹⁴, ¹Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Currently: GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ³currently: Ghent University, Ghent, Belgium & Cambridge University, Cambridge, United Kingdom, ⁴Dept. of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁷Rheumatology, Amsterdam Rheumatology & Immunology Center, Reade, Amsterdam, Netherlands, ⁸Dept Clin Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, ⁹Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ¹⁰Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ¹¹Clinical Immunology & Rheumatology, ARC | Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ¹²Current address: GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom, ¹³Department of Genome Analysis, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, ¹⁴Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The onset of seropositive rheumatoid arthritis (RA) is preceded by the presence of specific autoantibodies in the absence of synovial inflammation. Only a subset…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].